Stefano Pallanti is Visiting Professor at Albert Einstein College of Medicine, New York, USA, Visiting Professor at Imperial College, London, UK and Adjunct Associate Professor at Icahn School of Medicine at Mount Sinai, New York, USA where he served as the Founder and Director of the Strategic Center of Excellence for OCD, Impulsive and Behavioural Addiction. He is Associate Professor of Psychiatry at the University of Florence in Italy where he has been Chair of Education and Director of the Residency Program of Psychiatr since 2010.

 

He is an Executive Committee Member, Fellow Member and the Scientific Board of ECNP ( European College of Neuropsychopharmacology) and serves in its Educational Committee. He is the Advisory Council of the International Center for Autism Research and Education (Icare4autism, New York), an International Fellow and the International Advisory Board of the American Psychiatric Association for the Diagnostic and Statistical Manual of Mental Disorders, for DSM-IV and the Obsessive Compulsive Disorder Spectrum Workgroup for the DSM-V.

 

He is a member of the board of directors of the International College for Obsessive-Compulsive Syndromes (ICOCS) and an Associate Director of the European Certificate, International Master Course in Affective Neuroscience. He served as a member of board of directors for Clinical TMS Society from May 2013 to May 2017. Dr. Pallanti is a member of the New York Society of Psychiatry.

 

His current collaborative research projects are in the areas of treatment-resistant OCD, PANDAS, Anxiety in Psychosis, Anxiety Disorder in pregnancy, the puerperium and postpartum, the ADHD – OCD spectrum and the Bipolar disorder. He is particularly interested in rTMS and Neuromodulation treatments and research in multi-disciplinary context. He is a member of the Editorial Board of the American Journal of Psychiatry and of the CNS Spectrums, where he is also a columnist and International Editor. He is an International fellow member of American Psychiatric Publishing Inc. 

Peer-Reviewed Original Research Publications (160 total)

1. Faravelli C, Sacchetti E, Ambonetti A, Conte G, Pallanti S, Vita A. Recent life events and affective disorder revisited. British Journal of Psychiatry. 1986 Mar;148:288-95.

 

2. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and incomplete recovery from index episode. American Journal of Psychiatry. 1986 Jul;143(7):888-91.

 

3. Faravelli C, Pallanti S. Clomipramine by different routes of administration: short- and long-term efficacy and predictors of clinical outcome. Psychopharmacol Bull. 1987;23(3):459-63.

 

4. Faravelli C, Pallanti S, Frassine R, Albanesi G, Guerrini Degl'Innocenti B. Panic attacks with and without agoraphobia: a comparison. Psychopathology. 1988;21(1):51-6.

 

5. Faravelli C, Pallanti S, Strik WK. [Stress load and schizophrenic disorder]. Nervenarzt. 1988 Apr;59(4):237-9. German.

 

6. Faravelli C, Pallanti S. Recent life events and panic disorder. American Journal of Psychiatry. 1989 May;146(5):622-6.

 

7. Smeraldi E, Orsini A, Gasperini M, Sciuto G, Battaglia M, Cassano GB, Perugi G, Faravelli C, Pallanti S, Bressa G. Familial analysis of panic disorder and agoraphobia. Journal of Affective Disorders, 1989, vol.17, p.1-8. ISSN: 0165-0327.

 

8. Faravelli C, Guerrini Degl'Innocenti B, Aiazzi L, Incerpi G, Pallanti S. Epidemiology of mood disorders: a community survey in Florence. Journal of Affective Disorders. 1990 Oct;20(2):135-41.

 

9. Faravelli C, Panichi C, Pallanti S, Paterniti S, Grecu LM, Rivelli S. Perception of early parenting in panic and agoraphobia. Acta Psychiatrica Scandinavica. 1991 Jul;84(1):6-8.

 

10. Faravelli C, Pallanti S, Biondi F, Paterniti S, Scarpato MA. Onset of panic disorder. American Journal of Psychiatry. 1992 Jun;149(6):827-8.

 

11. Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biological Psychiatry. 1992 Jul 1;32(1):91-5.

 

12. Zaccara G, Gangemi PF, Muscas GC, Paganini M, Pallanti S, Parigi A, Messori A, Arnetoli G. Smooth-pursuit eye movements: alterations in Alzheimer's disease. Journal of the Neurological Science. 1992 Oct;112(1-2):81-9.

 

13. M.Weissman, L.Bobins, J.Escobar, R.Bland, G.Canino, H.Wittchen, C.Faravelli, S.Pallanti, J.Lepine, P.Pariente, E.Karam, J.Wells, H.Hwu, G.Klerman, P.Lavori, W.Maier (1992). The changing rate of depression. JAMA, vol. 268, p. 3098-3105, ISSN: 0098-7484.

 

14. Pallanti S., Pavia R.S. A demencia emu ma prospectiva psico (pato) lògica. [Dementia in a psycho(patho)logical perspective] Jornal Brasiliero de Psiquiatria [Brazilian Journal of Psychiatry] 41 (9), 447-50. Ott. 1992.

 

15. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Assessment of onset of panic disorder in relatrion to onset of agoraphobia-replay. American Journal of Psychiatry 150 (9), 1437-1437. 1993-09-01.

 

16. Mortilla M, Amaducci L, Bruni A, Montesi MP, Trubnikov A, De Cataldo S, Pallanti S, Pazzagli A, Grecu L, Servi P, et al. Absence of APP713 mutation in Italian and Russian families with schizophrenia. Neuroscience Letters 1994 Jan 3;165(1-2):45-7.

 

17. Grassi E, Mortilla M, Amaducci L, Pallanti S, Pazzagli A, Galassi F, Guarnieri BM, Petruzzi C, Bolino F, Ortenzi L, Nistico R, De Cataldo S, Rossi A, Sorbi S. No evidence of linkage between schizophrenia and D2 dopamine receptor gene locus in Italian pedigrees. Neuroscience Letters 1996 Mar 15;206(2-3):196-8.

 

18. Pallanti S, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L, Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive-compulsive disorder. Biological Psychiatry. 1996 Dec 1;40(11):1164-72.

 

19. Pallanti S, Koran LM. Two case report. CNS Spectrums 1996, vol.1, p.54-57, ISSN: 1092-8529.

 

20. Bersani G., Saito A. Pallanti S. Sasso E., Tosca P. Clinical variables and response to citalopram in Major Depression: an open multicentric study. Rivista di Psichiatria 32, 260-267, 1997.

 

21. Pallanti S. Personality Disorders: Myths and Neuroscience. CNS Spectrums 2, 53-63, 1997.

 

22. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry. 1997 Mar;154(3):396-401.

 

23. Pallanti S, Quercioli L, Pazzagli A. Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. American Journal of Psychiatry. 1997 Jun;154(6):792-8.

 

24. Ramacciotti A, Pallanti S, Pazzagli A. A setting including psychotherapy and psychopharmacological treatment in a case of anorexia nervosa with obsessive compulsive disorder comorbidity. Eating and Weight Disorders. 1997 Dec;2(4):222-8.

 

25. Inzitari D, Pantoni L, Lamassa M, Pallanti S, Pracucci G, Marini P. Emotional arousal and phobia in transient global amnesia. Archives of Neurology. 1997 Jul;54(7):866-73.

 

26. Pallanti S, Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa. Eating and Weight Disorders. 1997 Dec;2(4):216-21.

 

27. Pallanti S, Quercioli L, Zaccara G, Ramacciotti AB, Arnetoli G. Eye movement abnormalities in anorexia nervosa. Psychiatry Research. 1998 Mar 20;78(1-2):59-70.

 

28. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1998 May;8(2):121-6.

 

29. Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. Biological Psychiatry. 1998 Aug 1;44(3):220-7.

 

30. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-203, 1999-01-01.

 

 

 

31. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. American Journal of Psychiatry. 1999 May;156(5):796. 10327919.

 

32. Pallanti S, Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Research. 1999 Jun 30;86(3):239-49.

 

33. Pallanti S, Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, Pini S, Cassano GB. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. American Journal of Psychiatry. 1999 Jul;156(7):1094-6.

 

34. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. European Psychiatry. 1999 Apr;14(2):101-6.

 

35. Pallanti S, Quercioli L, Pazzagli A. Basic symptoms and P300 abnormalities in young schizophrenic patients. Comprehensive Psychiatry. 1999 Sep-Oct;40(5):363-71.

 

36. Pini S, Dell'Osso L, Mastrocinque C, Marcacci G, Papasogli A, Vignoli S, Pallanti S, Cassano G. Axis I comorbidity in bipolar disorder with psychotic features. British Journal of Psychiatry 1999.467-71.

 

37. Pallanti S, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. Journal of Clinical Psychiatry. 1999 Dec;60(12):819-23.

 

38. Di Russo F, Zaccara G, Ragazzoni A, Pallanti S. Abnormal visual event-related potentials in obsessive-compulsive disorder without panic disorder or depression comorbidity. Journal of Psychiatric Research. 2000 Jan-Feb;34(1):75-82.

 

39. Pallanti S, Quercioli L. Shame and psychopathology. CNS Spectrums. 2000 Aug;5(8):28-43.

 

40. Pallanti S, Quercioli L, Pazzagli A. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine. CNS Spectrums. 2000 Sep;5(9):29-43.

 

 

 

41. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Comprehensive Psychiatry. 2000 Nov-Dec;41(6):446-9.

 

42. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. European Neuropsychopharmacology. 2001 Apr;11(2):169-72.

 

43. Hollander E., Bienstock C.A., Koran L.M., Pallanti S., Marazzini D., Rasmussen S.A., Ravizza L., Benkelfat C., saxena S., Greenberg D.B., Sasson Y., Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry 63, 20-29, 12-2001.

 

44. Pallanti S., Quercioli L. Alternative route of administration and titration of SRIs in anxious resistant patients:Two day-hospital experiences. European Neuropsychopharmacology 11, S312, 2001-12-31.

 

45. Ramacciotti A, Sorbello M, Pazzagli A, Vismara L, Mancone A, Pallanti S. Attachment processes in eating disorders. Eat Weight Disord. 2001 Sep;6(3):166-70.

 

46. Presta S, Marazziti D, Dell'Osso L, Pfanner C, Pallanti S, Cassano GB. Kleptomania: clinical features and comorbidity in an Italian sample. Comprehensive Psychiatry. 2002 Jan-Feb;43(1):7-12.

 

47. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry. 2002;63 Suppl 6:20-9.

 

48. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology. 2002 Jun;5(2):181-91.

 

49. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. Journal of Clinical Psychiatry. 2002 Jul;63(7):559-64.

 

50. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry. 2002 Sep;63(9):796-801.

 

51. Pallanti S, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. Journal of Clinical Psychiatry. 2002 Nov;63(11):1034-9.

 

52. Buchsbaum M.S., Hollander E., Pallanti S., Baldini-Rossi N. Brikman A.M., Platholi J., Sood E. Positron emission tomography. Imaging of risperidone augmentation in SRI-refractory patients. Biological Psychiatry 51 (8), 47S-47S, 2002-04-14.

 

53. Pallanti S., Rossi N.B., Friedberg J., Hollander E. Psychobiology of Impulse-Control Disorders Not Otherwise Specified (NOS). Biological Psychiatry 2003, 1315-1329.

 

54. Sood ED, Pallanti S, Hollander E. Diagnosis and treatment of pathologic gambling. Current Psychiatry Reports. 2003 May;5(1):9-15.

 

55. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology. 2003 Dec;6(4):397-401.

 

56. Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. American Journal of Psychiatry. 2004 Jan;161(1):53-8.

 

57. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Journal of Clinical Psychiatry. 2004 Oct;65(10):1394-9.

 

58. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2004;65 Suppl 14:6-10.

 

59. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? American Journal of Psychiatry. 2005 Jan;162(1):137-45.

 

60. Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological treatments of pathological gambling. Journal of Gambling Studies. 2005 Spring;21(1):99-110.

 

61. Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, Licalzi EM, Tang C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. Biological Psychiatry. 2005 Apr 1;57(7):733-42.

 

62. Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatologic Clinics. 2005 Oct;23(4):601-8.

 

63. Pallanti S, Lotti T, Urpe M. Psychoneuroimmunodermatology of atopic dermatitis: from empiric data to the evolutionary hypothesis. Dermatologic Clinics. 2005 Oct;23(4):695-701.

 

64. Hollander E, Pallanti S, Baldini Rossi N, Sood E, Baker BR, Buchsbaum MS. Imaging monetary reward in pathological gamblers. World Journal of Biological Psychiatry. 2005;6(2):113-20.

 

65. Pallanti S, Lassi S, La Malfa G, Campigli M, Di Rubbo R, Paolini G, Cesarali V. Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. Clinical Practice & Epidemiology in Mental Health. 2005 Nov 15;1:24.

 

66. Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). Journal of Gambling Studies. 2005 Winter;21(4):431-43.

 

67. Rossi A, Rucci P, Mauri M, Maina G, Pieraccini F, Pallanti S, Endicott J; (For the EQUIP group). Reliability and validity of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. Quality of Life Research. 2005 Dec;14(10):2323-8.

 

68. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2006 May;30(3):400-12.

 

69. Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology. 2006;53(3):157-68.

 

70. Pallanti S, Bernardi S, Quercioli L, DeCaria C, Hollander E. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. CNS Spectrums. 2006 Dec;11(12):956-64.

 

71. Pallanti S, Bernardi S, Quercioli L. The Shorter PROMIS Questionnaire and the Internet Addiction Scale in the assessment of multiple addictions in a high-school population: prevalence and related disability. CNS Spectrums. 2006;11(12):966-74.

 

72. Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram. Clinical Practice & Epidemiology in Mental Health. 2006;13;2:35.

 

73. Hollander E, Kim S, Khanna S, Pallanti S. Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. CNS Spectrums. 2007 Feb;12(2 Suppl 3):5-13.

 

74. Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. International Clinical Psychopharmacology 2007;22(6):313-22.

 

75. Pallanti S, Sandner C. Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. International Journal of Psychiatry in Clinical Practice. 2007; 11(3): 233-238.

 

76. Pallanti S. Transcultural observations of obsessive-compulsive disorder. American Journal of Psychiatry. 2008 Feb;165(2):169-70.

 

77. Pallanti S, Masetti S, Bernardi S, Innocenti A, Markella M, Hollander E. Obsessive compulsive disorder comorbidity in DBA. Clinical Practice & Epidemiology in Mental Health. 2008 Mar 10;4:6.

 

78. La Malfa G, Lassi S, Bertelli M, Pallanti S, Albertini G. Detecting attention-deficit/hyperactivity disorder (ADHD) in adults with intellectual disability The use of Conners' Adult ADHD Rating Scales (CAARS). Research in Developmental Disabilities. 2008 Mar-Apr;29(2):158-64.

 

79. Pallanti S. Brain plasticity and brain stimulation in neuropsychiatry: toward individualized medicine. CNS Spectrums. 2008 Apr;13(4):287-92.

 

80. Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W, Goodman CR, LiCalzi EM, Newmark R, Pallanti S. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral and cingulated metabolism. Neuropsychobiology. 2008;58(1):37-47.

 

81. Pallanti S, Hollander E. Obsessive-compulsive disorder spectrum as a scientific "metaphor". CNS Spectrums. 2008 Sep;13(9 Suppl 14):6-15.

 

82. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., Pallanti S., Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in the treatment of obsessive-compulsive disorder. Biological Psychiatry 63 (7), 170S-170S, 2008-04-01.

 

83. Pallanti S, Bernardi S. Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety: a critical review. International Clinical Psychopharmacology 2009 Jul;24(4):163-73.

 

84. Faravelli C, Lo Sauro C, Castellini G, Ricca V, Pallanti S. Prevalence and correlates of mental disorders in a school-survey sample. Clinical Practice & Epidemiology in Mental Health 2009 Nov 24;5:1-8.

 

85. Pallanti S, Castellini G, Chamberlain SR, Quercioli L, Zaccara G, Fineberg NA. Cognitive event-related potentials differentiate schizophrenia with obsessive-compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC symptoms. Psychiatry Research. 2009 Nov 30;170(1):52-60.

 

86. Potenza MN, Koran LM, Pallanti S. The relationship between impulse-control disorders and obsessive-compulsive disorder: a current understanding and future research directions. Psychiatry Research. 2009 Nov 30;170(1):22-31.

 

87. Bernardi S, Pallanti S. Internet addiction: a descriptive clinical study focusing on comorbidities and dissociative symptoms. Comprehensive Psychiatry. 2009 Nov-Dec;50(6):510-6.

 

88. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs. 2009 Dec;23(12):1047-55.

 

89. Lisanby SH, Pallanti S, Schlaepfer TE. FDA considers classification of ECT. CNS Spectrums. 2009 Dec;14(12):668-70.

 

90. Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? Neuroscience. 2010;5;167(2):323-8.

 

91. Pallanti S, Bernardi S, Raglione LM, Marini P, Ammannati F, Sorbi S, Ramat S. Complex repetitive behavior: punding after bilateral subthalamic nucleus stimulation in Parkinson's disease. Parkinsonism and Related Disorder. 2010 Jul;16(6):376-80.

 

92. Cecchelli C, Grassi G, Pallanti S. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression. Case Reports in Medicine. 2010;2010:836214.

 

93. Schlaepfer TE, Lisanby SH, Pallanti S. Separating hope from hype: some ethical implications of the development of deep brain stimulation in psychiatric research and treatment. CNS Spectrums. 2010 May;15(5):285-7.

 

94. Pallanti S., Schlaepfer T.E., Lisanby S.H. The Clinical Future of Repetitive Transcranical Magnetic Stimulation and Depression: Separating Hope From Hype. CNS Spectrums 15 (9), 554-557, 2010.

 

95. Pallanti S, Haznedar MM, Hollander E, Licalzi EM, Bernardi S, Newmark R, Buchsbaum MS. Basal Ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study. Neuropsychobiology. 2010;62(2):132-8.

 

96. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood driven? World Psychiatry. 2010 Jun;9(2):96-7.

 

97. Bernardi S, Cortese S, Solanto M, Hollander E, Pallanti S. Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. World Journal of Biological Psychiatry. 2010 Jun;11(4):656-66.

 

98. Pallanti S, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E. Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine. Journal of Psychopharmacology. 2010 Jun;24(6):847-53.

 

99. Bernardi S, Pallanti S. Successful duloxetine treatment of a binge eating disorder: a case report. Journal of Psychopharmacology. 2010 Aug;24(8):1269-72.

 

100. Pallanti S, Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A, Zaccara G, Cincotta M. Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation investigation. Journal of Neurology. 2010 Aug;257(8):1362-8.

 

101. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Bruguà M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;3;10:67.

 

102. Pallanti S. Augmentation strategies in resistant obsessive-compulsive disorders (OCD), International Journal of Psychiatry in Clinical Practice 14, 15-16, 2010-11-01.

 

103. Pallanti S, Bernardi S, Allen A, Hollander E. Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. Journal of Psychopharmacology. 2010 Dec;24(12):1802-9.

 

104. Pallanti S. Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. CNS Spectrums. 2010 Mar;15(3):154-6.

 

105. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2011 May;72(5):716-21. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

 

106. Di Rollo A, Pallanti S. Phantom limb pain: low frequency repetitive transcranial magnetic stimulation in unaffected hemisphere. Case Reports in Medicine. 2011;2011:130751.

 

107. Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychological Medicine. 2011 Aug 16:1-13. *Provided study ideas and concept, participated in the drafting and revision of the manuscript, and provided mentorship to first author

 

108. Pallanti S, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications. Front Psychiatry. 2011;2:70.

 

109. Valenti R, Pescini F, Antonini S, Castellini G, Poggesi A, Bianchi S, Inzitari D, Pallanti S, Pantoni L. Major depression and bipolar disorders in CADASIL: a study using the DSM-IV semi-structured interview. Acta Neurologica Scandinavica. 2011 Dec;124(6):390-5. *Participated extensively in conception and trial design, acquisition, analysis and interpretation of data, participated in drafting, reviewing and critical revision of the manuscript

 

110. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World Journal of Biological Psychiatry. 2012; 13(7):510-6.

 

111. Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. Journal of the European Academy of Dermatology and Venereology. 2012; 26(7):861-7. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

 

112. Pallanti S, Cantisani A, Grassi G, Antonini S, Cecchelli C, Burian J, Cauli G, Quercioli L. rTMS age-dependent response in treatment resistant depressed subjects: a mini-review, CNS Spectrums (2012), 17, 24-30.

 

113. S. Pallanti, A. Di Rollo, S. Antonini, E. Hollander and L.Quercioli Low Frequency rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant Depression: Cognitive Improvement is Independent from Clinical Response, Neuropsychobiology 2012 Jun; 65(4):227-35.

 

114. Moretti S., Arunachalam M., Colucci R., Pallanti S., Kline JA., Berti S., Lotti F., Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. Journal of the European Academy of Dermatology and Venereology 2012; 26 (7), 861-867. *Participated extensively in conception, drafting, reviewing and critical revision of the manuscript

 

115. Bandinelli F, Prignano F, Bonciani D, Pallanti S, Lotti T, Salaffi F, Bartoli F, Candelieri A, Giovannini L, Maddali Bongi S, Matucci-Cerinic M. Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). Clinical and Experimental Rheumatology. 2012;31(2):318-9. *Participated extensively in conception, drafting, reviewing and critical revision of the manuscript

 

116. Baldwin DS, Pallanti S, Zwanzger P. Developing a European Research Network to Address Unmet Needs in Anxiety Disorders. Neuroscience and Biobehavioral Reviews. 2013; 37(10 Pt 1):2312-7. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

 

117. Valenti R, Salvadori E, Pescini F, Poggesi A, Castellini G, Antonini S, Bianchi S, Inzitari D, Pallanti S, Pantoni L., Facial Affect Recognition in CADASIL Patients., Archives of Clinical Neuropsychology 2013;28(1):65-71. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

 

118. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti S, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World Journal of Biological Psychiatry. 2013;(2): 121-128. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

 

119. Pallanti S, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia. Current Psychiatry Reports. 2013;15(5):354.

 

120. Dell’Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Nicolini H, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder, a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). European Neuropsychopharmacology. 2013 Aug; 23(8):865 71. *Participated extensively in conception and trial design, acquisition and analysis of data, participated in drafting, reviewing and critical revision of the manuscript

 

121. Pallanti S, Grassi G, Tofani T, Spitoni S. Pharmacological Treatments for Behavioral Addictions: From Behavioral Dimensions to the Research Domain Criteria Based Target. Current Psychopharmacology, 2013; 2(3):183-189.

 

122. Marras A, Pallanti S. Transcranial magnetic stimulation for the treatment of pharmacoresistant nondelusional auditory verbal hallucinations in dementia. Case Reports in Psychiatry. 2013; 2013:930304.

 

123. Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectrums. 2014; 19(1):50-61.

 

124. Carelli R, Pallanti S. Streptococcal infections of skin and PANDAS. Dermatologic Therapy. 2014 Jan; 27(1):28-30.

 

125. Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, Pallanti S. Hypocondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. CNS Spectrums. 2014; 9(4):340-6.

 

126. Van Ameringen S, Simpson W, Patterson B, Dell’Osso B, Finebg n, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, Pallanti S, Stein DJ, Zohar, J. Pharmachological treatment strategies in obsessive-compulsive disorder: A cross-sectional view in nine international OCD centers. Journal of Psychopharmacology 2014; 28(6):596-602. *Participated extensively in conception and trial design, authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript

 

127. Di Rubbo R., Sogaro E., Pallanti, S. Communicative evolutive psychotherapy adapted for the psychodynamic group setting in the treatment of pathological interpersonal dynamics of identity. Dynamische Psychiatrie. 2013; 46(3): 204-233.

 

128. Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive disorders. Expert opin Emerg Drugs, 2014 Mar; 19(1):66-77.

 

129. Pallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in resistant mixed states: An exploratory study. J Affect Disord. 2014; 157:66-71.

 

130. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 2014; 24(3):375-380.

 

131. Pallanti S, Grassi G, Ramella Cravaro V, Goodman W.K. From Psychopathology to neurocircuits: what we can learn from DBS? The case of obsessive-compulsive disorder. J. Psychopathol. 2014;20:27-32.

 

132. Aguglia E, Biggio G, Signorelli MS, Mencacci C; Steering Committee on behalf of the STIMA-D Investigators. Italian Study on Depressive Disorders (STudio Italiano MAlattia Depressiva, or STIMA-D): a nationwide snapshot of the status of treatment for major depression. Pharmacopsychiatry.2014 May;47(3), 105-10. * Collaborator: Pallanti S. *Acquisition of data

 

133. Pallanti S, Tofani T, Zanardelli M, Di Cesare mannelli L, Ghelardini C. BDNF and ARTEMIN are increased in drug-naive non-depressed GAD patients: preliminary data. International Journal of Psychiatry in Clinical Practice. 2014; 18(4):255-60.

 

134. Lochner C, Fineberg NA, Zohar J, Van Ameringen M, Juven_Wetzler A, Altamura AC Cuzen NL, Hollander E, Denys D, Nicolini H, Dell'Osso B, Pallanti S, Stein DJ, Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorder (ICOCS). Comprehensive Psychiatry. 2014;55(7):1513-9. *Participated extensively in conception and trial design, drafting, reviewing and critical revision of the manuscript

 

135. Pallanti S, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder comorbidity. Expert Opin Pharmacother. 2014;15(17):2543-52.

 

136. Mucci A, Rucci P, Rocca P, Bucci P, Gibertoni D, Merlotti E, Galderisi S, Maj M; Italian Network for Research on Psychoses. The Specific Level of Functioning Scale: construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. Schizophrenia Research. 2014; 159(1):144-50. *Collaborator: Pallanti S. *Acquisition of data

 

137. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell'Osso L, De Ronchi D, Di Emidio G, Di Giannantonio M, Fagiolini a, Marchesi C, Monteleone P, Oldani L, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A, Zeppegno P, Maj M; Italian Network for Research on Psychoses. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014; 13(3):275-87. *Collaborator: Pallanti S. *Acquisition of data

 

138. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive-behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation. 2015; 8(1):160-1.

 

139. Pallanti S, Salerno L. Raising attention to attention deficit hyperactivity disorder in schizophrenia. World Journal of Psychiatry. 2015;5(1):47-55.

 

140. Dell'Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Van Ameringen M, Lochner C, Hranov N, Karamustafalioglu O, Hranov L, Zohar J, Denys d, Altamura AC, Menchon JM. Cigarette smoking in patients with obsessive compulsive disorder: a report from International College of Obsessive Compulsive Spectrum Disorder (ICOCS). CNS Spectrums. 2015; 20(5):469-73. *Participated extensively in conception, participated in drafting, reviewing and critical revision of the manuscript

 

141. Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorder: Implications for interventions and therapeutics. World Journal of Biological Psychiatry. 2015;15:1-13. *Authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript

 

142. Grant J E, Fineberg N, Van Ameringen A, Cath D, Visser H, Carmi L, Pallanti S, Hollander E, Van Balkom A J, New treatment models for compulsive disorders. European Neuropsychopharmacology 2016; 26(5):877-84. *Participated extensively in conception, acquisition of data, authorship of sections of the manuscript

 

143. Grassi G, Pallanti S, Righi L, Figee M, Mantione M, Denys D, Piccagliani D, Rossi A, Stratta P. Think twice: Impulsivity and decision making in obsessive-compulsive disorder. Journal of Behavioral Addiction 2015;4(4):263-72. *Provided study ideas, participated in the drafting, reviewing and revision of the manuscript, and provided mentorship to first author

 

144. Pallanti S, Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial. Journal of Psychopharmacology. 2016; 30(6):568-78.

 

145. Menchon JM, Van Ameringen M, Dell’Osso B, Denys D, Figee M, Grant JE, holander E, Marazziti D, Nicolini H, Pallanti S, Ruck R, stein DJ, Andersson E, bipeta R, Cath DC, drummond L, Feusner J, Geller DA, Hranov , lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O’Kearney R, pasquini M, Perez Rivera R, Poyurovsky M, Real E, do Rosario MC, Sreni N, Swinson RP, Vulink N, Zphar J, Fineberg N. Standards of care for obsessive-compulsive disorders centres. International Journal of Psychiatry in Clinical Practice. 2016;20(3):204-8. *Participated extensively in conception and trial design, acquisition of data and in drafting

 

146. Marras A, Fineberg N, Pallanti S. Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11. CNS Spectrums. 2016;21(4):324-33.

 

147. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, bourin M, Chamberlain SR, Cinosi E, Davies S, Domscchke K, Fineberg N, Grunblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Strohle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P. Biological markers for anxiety disordrs, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophisiology and neurocognition. World Journal of Biological Psychiatry. 2016;15:1-53. *Participated extensively in conception and trial design, acquisition,authorship of sections of the manuscript

 

148. Dell’Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, altamura AC, Marazziti D, Pallanti S, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hrano L, Figee M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). International Journal of Psychiatry in Clinical Practice. 2016;19:1-8. *Participated extensively in conception and trial design, acquisition of data and in drafting

 

149. Pallanti S. ICD and DSM: Neuroplasticity and Staging are still missing. CNS Spectrums. 2016 Aug:21(4):276-8.

 

150. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Blasi G, Comparelli A, Di Giannantonio M, Goracci A, Marchesi C, Monteleone P, Montemagni C, Pinna F, Roncone R, Siracusano A, Stratta P, Torti MC, Vita A, Zeppegno P, Chieffi M, Maj M; Italian Network for Research on Psychoses.. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first degree relatives. Schizophr Res 2016; 175(1-3):154-60. *Collaborator: Pallanti S. *Participated extensively in conception and trial design, acquisition, analysis of data, reviewing and critical revision of the manuscript

 

151. Rocca P, Galderisi S, Rossi A, Bertolino A, Rucci P, Gibertoni D, Montemagni C, Sigaudo M, Mucci A, Bucci P, Acciavatti T, Aguglia E, Amore M, Bellomo A, De Ronchi D, Dell'Osso L, Di Fabio F, Girardi P, Goracci A, Marchesi C, Monteleone P, Niolu C, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Zeppegno P, Maj M; Italian Network for Research on Psychoses. Social cognition in people with schizophrenia: a cluster-analytic approach. Psychol Med 2016 Oct;46(13):2717-2729 *Collaborator: Pallanti S. *Participated extensively in conception and trial design, acquisition, participated in drafting, reviewing and critical revision of the manuscript

 

152. Menchón JM, van Ameringen M, Dell'Osso B, Denys D, Figee M, Grant JE, Hollander E, Marazziti D, Nicolini H, Pallanti S, Ruck C, Shavitt R, Stein DJ, Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov G, Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R, Pasquini M, Pérez Rivera R, Poyurovsky M, Real E, do Rosário MC, Soreni N, Swinson RP, Vulink N, Zohar J, Fineberg N. Standards of care for obsessive-compulsive disorder centres. Int J Psychiatry Clin Pract. 2016 Sep;20(3):204-8. *Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript

 

153. Giordano F, Cavallo M, Spacca B, Pallanti S, Tomaiuolo F, Pieraccini F, Fagiolini A, Grandoni M, Melani F, Zicca A, Sestini S, Genitori L. Deep Brain Stimulation of the Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive Behaviour. Stereotact Funct Neurosurg. 2016 Nov 1;94(6):371-378. *Participated extensively in conception and trial design, acquisition of data and in drafting

 

154. Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, Pallanti S, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hranov L, Figee M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). Int J Psychiatry Clin Pract. 2016 Nov;20(4):210-7. *Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript

 

155. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation. J Psychiatr Res. 2016 Dec;83:240-248.

 

156. Chiariello F, Spitoni S, Hollander E, Pallanti S. An expert opinion on PANDAS/PANS: highlights and controversies. International Journal of Psychiatry in Clinical Practice 2017; 1-8 Published online: 13 Feb 2017

157. Salerno L, Makris N, Pallanti S. Sleep disorders in adult ADHD: a key feature. Journal of Psychopathology 2016;22:135-140.

 

158. Pallanti S. Biological Markers for Anxiety Disorders, OCD and PTSD – A Consensus Statement – Part II: Neurochemistry, Neurophysiology and Neurocognition. The World Journal of Biological Psychiatry World J Biol Psychiatry. 2017 Apr;18(3):162-214.

159. Dell'Osso B, Benatti B, Arici C, Palazzo C, Altamura AC, Hollander E, Fineberg N, Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, Pallanti S, van Ameringen M, Lochner C, Karamustafalioglu O, Hranov L, Figee M, Drummond L, Rodriguez CI, Grant J, Denys D, Menchon JM, Zohar J. Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS Spectr. 2017 Mar 16:1-8.

160. Dell’Osso B, Marazziti D, Albert U, Pallanti S, Gambini G, Tundo A, Zanaboni C, Servello D, Rizzo R, Scalone L, Benatti B, Altamura C, Porta M. Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. Int J Psychiatry Clin Pract. 2017 Jun;21(2):156-159.

 

 

 

 

Peer-Reviewed Editorials

 

1. Pallanti S. The anxiety-psychosis spectrum. CNS Spectrums. 2000 Sep;5(9):22.

2. Pallanti S., Transcultural Observations of Obsessive-Compulsive disorder, American Journal of Psychiatry, 165:2, February 2008

3. Pallanti S., Problematic Internet Use: is it more compulsory than rewarding or mood driven? World Psychiatry.2010 Jun;9(2):96-7.

4. Pallanti S. Transcultural observations of obsessive-compulsive disorder. American Journal of Psychiatry. 2008 Feb;165(2):169-70.

5. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood driven? World Psychiatry. 2010 Jun;9(2):96-7.

6. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive-behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation.2014.10.18.

 

 

Peer-Reviewed Abstracts

 

1. Pallanti S., Zuccarini S., Rivelli A., Quercioli L., Pazzagli A. Depth perception in schizophrenia. Biological Psychiatry 35 (9), 637-638. 1994-05-01.

2. Koran L., Sallee F., Pallanti S., Paiva R., Quercioli L. Intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Psychopharmacology Bulletin 32 (3), 466-466. Nov. 1996.

3. Di Russo F., Zaccara G., Pallanti S., Gangemi P., Lori S., Ragazzoni A. Visual event-related potentials in obsessive-compulsive disorders. Electroencephalography and Clinical Neurophysiology 103 (1), 211-211, Jul 1997.

4. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-203, 1999-01-01.

5. Russo F., Zaccara G., Ragazzoni A. Pallanti S. Abnormal visual ERPs in obsessive-compulsive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 207-207, 1999-01-01.

6. Pallanti S., Quercioli L. Reboxetine in bulimia nervosa: An open study. Biological Psychiatry 49 (8), 105S-106S. 2001-04-05.

7. Quercioli L., Bruscoli M., Pallanti S. P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. European Neuropsychopharmacology 14, S186, 2004-10-31.

8. Pallanti S., Quercioli L. Reboxetine in bulimia nervosa: An open study. Biological Psychiatry 49 (8), 105S-106S. 2001-04-05.

9. Quercioli L., Bruscoli M., Pallanti S. P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. European Neuropsychopharmacology 14, S186, 2004-10-31.

10. Pallanti S., Baker B.R., Chaplin W., Kim S., De Caria C., Bernardi S., Hollander E., Noradrenergic function in pathological gambling. Biological Psychiatry. 2006;59 (8), 32S-32S.

11. Bernardi S., Ramat S., Raglione L., Marini P., Sorbi S., Ammannati F., Pallanti S. Punding after bilateral subthalamic nucleus stimulation in Parkinson’s disease. European Psychiatry 23, S350-S351.

12. Cincotta M., Borgheresi A., Pampaloni I., Giovannelli F., Bernardi S., Cantisani A., Zaccara G., Pallanti S. P27-7 Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation study. Clinical Neurophysiology 121, s265, 2010-20-31.

 

 

Peer-Reviewed Letters and Commentary

 

1. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. American Journal of Psychiatry. 1999 Nov;156(11):1834-5.

2. Pallanti S. "Dr. Pallanti Replies." American Journal of Psychiatry, 2000 157(5):840-a–840.

3. Hollander E, Pallanti S. "5-HT1D Function and Repetitive Behaviors." American Journal of Psychiatry, 2001 158(6):972-a–973.

4. Pallanti S, Quercioli L, Hollander E. "Dr. Pallanti and Colleague Reply." American Journal of Psychiatry, 2005 162(2): 400-a–401.

5. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Dr. Faravelli and Associates Reply. American Journal of Psychiatry 150 (9), 1437-1437. 1993-09-01.

6. Grassi G, Figee M, Stratta P, Rossi A, Pallanti S. Response to Cognitive impulsivity and the behavioral addiction model of obsessive-compulsive disorder: Abramovitch and McKay (2016). J Behav Addict. 2016 Sep;5(3):398-400.

7. Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 1994 Jun;14(3):216-8.

8. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. American Journal of Psychiatry. 1999 Nov;156(11):1834-5.

9. Hollander E, Pallanti S. 5-HT(1D) function and repetitive behaviors. American Journal of Psychiatry. 2001 Jun;158(6):972-3.

10. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. American Journal of Psychiatry. 1999 May;156(5):796.

 

 

Peer-Reviewed Book Reviews

 

1. Pallanti S. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. American Journal of Psychiatry 1999;156:1108a-1109.

2. Pallanti S. Panic Disorder: Clinical Diagnosis, Management and Mechanism. American Journal of Psychiatry 158(7), 1176-a-1177. 2001-07-01. Book Review

3. Pallanti S. Panic Disorder: Clinical Diagnosis, Management and Mechanism. American Journal of Psychiatry 158(7), 1176-a-1177. 2001-07-01.

4. Pallanti S. Review of perfectionism: theory, research and treatment. American Journal of Psychiatry 2004, vol.161 (8).

 

 

Other Publications

 

1. Pallanti S., Strategies for Treatment Resistant OCD, Psychiatric Times, Oct. 2014.

2. Pallanti S., Book Review: Comprehensive care of schizophrenia: a textbook of clinical management, 2nd edition. American Journal of Psychiatry. 2013 Jan 1;170(1):125-126.

3. Pallanti S. Images in Psychiatry. Ugo Cerletti. 1877-1963 Essay. American Journal of Psychiatry 156.630-630, 1999.

4. Pallanti S. Vincenzo Chiarugi, 1759-1820. American Journal of Psychiatry. 1996 Jul;153(7):944.

5. Pallanti S. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. American Journal of Psychiatry 1999;156:1108a-1109.

6. Pallanti S. From impulse-control disorders toward behavioral addictions. CNS Spectrums. 2006;11(12).921-922.

7. Pallanti S. Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. CNS Spectrums. 2010 Mar;15(3):154-6.

8. Pallanti S., Quercioli L. SSRIs in the treatment of premenstrual dysphoric disorder. Nefazodone: An open trial. European Neuropsychopharmacology 10(S3), 127-128, 2000-09-30.

 

Book Chapters

 

1. Pharmacological treatment of Autism Spectrum Disorders, pp. 151 – 166, Autism Spectrum Disorders- Phenotypes, Mechanisms and treatment, Edited by M. Leboyer, P. Chaste, Karger Medical and Scientific Publishers,2015

2. Approaches to treatment resistance, pp. 99-117, Obsessive Compulsive Disorder: Current Science and Clinical Practice, Edited by J. Zohar, John Wiley & Sons, LTD, 2012

3. Pathological Gambling, pp 251 – 289, Clinical Manual of Impulse Control Disorders, Edited by E. Hollander, D. Stein, American Psychiatric Publishing, 2006

4. Pharmacological Treatments, pp 189 – 200, Pathological Gambling: A Clinical Guide to Treatment,Edited by J. E. Grant, M. Potenza, American Psychiatric Publishing, 2004

5. Current and Experimental Therapeutics of Obsessive Compulsive Disorders, pp 1647 – 1664, Neuropsychopharmacology: The Fifth Generation of Progress, An Official Publication of the American College of Neuropsychopharmacology, Edited by K.L. Davis, D. Charney, J.T. Coyle and C. Nemeroff, Lippincott/Williams and Wilkins, 2002

6. Psychobiology of Impulse Control Disorders Not Otherwise Specified (NOS), pp 1315 – 1329, Biological Psychiatry, Edited by H. D’Haenen, J.A. den Boer, P. Willner, John Wiley & Sons Ltd., 2002

7. Sood E, Pallanti S, Hollander E. Serotonin reuptake inhibitors in the treatment of pathological gambling. Essential Psychopharmacology, pp 157-169, Edited by R. Murray, Cambridge University Press, 2002

8. Pallanti S., Rossi L., De Palma G., Checchi M., Muscas C., Faravelli C. Electroencephalogram mapping in sodium lactate-induced panic attacks: Preliminary results. Imaging of the Brain in Psychiatry and Related Fields, pp 281-284, Edited by K. Maurer, Springer, 1993

9. Enticott PG, Pallanti S, Ring R, Pascual-Leone A, Hollander E. New Technologies in Autism: Non-invasive Brain Stimulation. Autism Spectrum Disorders, Edited by E. Hollander, D. Fein, P.J. Hagerman. 2017 [in press]

 

Books

 

1. Pallanti, S., Psichiatria Elementare – Oltre il DSM-5 (Elementary Psychiatry – Beyond DSM-5), Carocci Editori, (2017)

2. Pallanti, S., Oltre la Schizophrenia (Beyond Schizophrenia) Edra LSWR (2015)

3. Pallanti, S. and Lauriello, J., Editors., Clinical Manual for Treatment of Schizophrenia, American Psychiatric Publighins. (2011)

4. Pallanti, S. and Formosa, A., Stress? No grazie, siamo resiliente, (Stress? No Thank you, We are resilient) Trevisini Editore. (2011)

5. Pallanti, S. and Lauriello, J., Clinical Manual for Schizophrenia, Edited by B. Hales, American Psychiatric Publishing. (2010)

6. Fossi, G., Pallanti, S., Psichiatria Elementare (Elementary Psychiatry), Carocci Editori, First edition 1999, Reprint 2015

7. Fossi G., Pallanti S., Psichiatria Elementare (Elementary Psychiatry), La Nuova Italia Scientifica S.p.A. Roma. First edition 1993, 6th edition 2008

8. Pallanti S., Bruscoli M., Le Emergenze Psichiatriche in Medicina, (Psychiatric Emergency in Medicine) Lippincott /Williams and Wilkins, (2006) sold exclusively by Innova Pharma SpA, Milano

9. Pallanti S., Koran L. M., Treatment of OCD Resistant Patients, Airon (2003)

10. Fossi G., Pallanti S., Manuale di Psichiatria (Manual of Psychiatry), Casa Editrice Ambrosiana, Milano (1993)

11. Pallanti S., Vivere con le Voci, Vivere nel Silenzio, (Live with Voices, Live in Silence, La nuova Italia Scientifica (1996)

 

Editor for an Italian Edition Book

BAARS-IV (Barkley Adult ADHD Rating Scale-IV), Russell A. Barkley, Hogrefe (2017), Pallanti S., Salerno L.

 

The American Psychiatric Publishing Textbook of Psychiatry, Edited by R. E. Hales, S. C. Yudofsky, L. W. Roberts, Sixth Edition, Edra (2014). Manuale di Psichiatria, Editors: Sacchetti E., Mencacci C., Aguglia E., Albert U., Altamura C., Bogetto F., Clerici M., Colombo C., Pallanti S., Santonastaso P., Smeraldi E., Zanalda E., Zuddas A.

 

Digital Publications

 

2009 – 2013 CD-ROM for the the Managing Anxiety in Practice (MAP) educational programme

 

Thesis

 

1. Pallanti S. (1983) Life events and Depression, Dissertation thesis for Medical

Doctorate Degree and European Medical License, University of Florence, School of Medicine, Florence, Italy.

 

2. Pallanti S. (1987) Life events and Schizophrenia, Dissertation thesis for PhD in Psychiatry, University of Florence, School of Medicine, Florence, Italy.

 

3. Pallanti S. (1992) Contingent Negative Variation (CNV) in normal elderly population, Dissertation thesis for PhD in Neurophysiopathology, University of Florence, School of Medicine, Florence, Italy.